Effects of antipsychotic drugs on cholecystokinin and preprotachykinin (substance P) mRNA expression in the rat hippocampal formation

European Neuropsychopharmacology

Volumn 10, Issue 5, 2000, Pages 355-363

  Zachrisson, Olof ^a,b   Nomikos, George G ^c,d   Marcus, Monica M ^c   Svensson, Torgny H ^c   Lindefors, Nils ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Sect Neuropsychopharmacology   (Sweden)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotic; Cholecystokinin; Entorhinal cortex; Hippocampus; Rat; Tachykinin

Indexed keywords

CHOLECYSTOKININ; CLOZAPINE; HALOPERIDOL; MESSENGER RNA; NEUROLEPTIC AGENT; SUBSTANCE P;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENTORHINAL CORTEX; HIPPOCAMPUS; MALE; MICROPHOTOGRAPHY; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

EID: 0033843617     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(00)00093-6     Document Type: Article

References (57)

1. Arnold S.E., Hyman B.T., VanHoesen G.W., Damasio A.R. Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch. Gen. Psychiat. 48:1991;625-632.
2. Bachus S.E., Hyde T.M., Herman M.M., Egan M.F., Kleinman J.E. Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics. J. Psychiatr. Res. 31:1997;233-256.
3. Bannon M.J., Lee J.-M., Giraus P., Young A., Affolter H.U., Bonner T.I. Dopamine antagonist haloperidol decreases substance P, substance K, and preprotachykinin mRNAs in rat striatonigral neurons. J. Biol. Chem. 261:1986;6640-6642.
4. Björklund A., Lindvall O. Dopamine-containing systems in the CNS. Björklund A., Hökfelt T. Classical transmitters in the CNS. Part I. 1984;55-122 Elsevier, New York.
5. Blacker D., Broberger C., Ögren S., Hökfelt T. Cholecystokinin B receptor antagonists enhance the locomotor response to the N-methyl-D-aspartate antagonists phencyclidine and dizocilpine maleate. Neuroscience. 76:1997;1057-1067.
6. Bogerts, B., Meertz, E., Schtinfeldt-Bausch, R., 1983. Limbic system pathology in schizophrenia: A controlled post mortem study. In: World Congress of Psychiatry. Wien.
7. Coggeshall R.E., Lekan H.A. Methods for determining numbers of cells and synapses: a case for more uniform standards of review. J. Comp. Neurol. 364:1996;6-15.
8. Cohen S.L., Knight M., Tamminga C.A., Chase T.N. Cholecystokininoctapeptide effects on conditioned-avoidance behaviour, stereotypy and catalepsy. Eur. J. Pharmacol. 83:1982;213-222.
9. Conley R.R., Schulz S.C., Baker R.W., Collins J.F., Bell J.A. Clozapine efficacy in schizophrenic nonresponders. Psychopharmacol. Bull. 24:1988;269-274.
10. Coward D.M. General pharmacology of clozapine. Br. J. Psychiatr. 160:1992;5-11.
11. Crawley J.N. Cholecystokinin-dopamine interactions. Trends Pharmacol. Sci. 12:1991;232-236.
12. de Witte P., Gewiss M., Roques B., Vanderhaeghen J.J. Neurolepticlikeproperties of cholecystokinin analogs: distinctive mechanisms underlying similar behavioral profiles depending on the route of administration. Peptides. 9:1988;739-743.
13. Delphs J.R., Dichter M.A. Cholecystokinin-octapeptide enhances synaptic activity in neurons cultured from rat cerebral cortex. Peptides. 6:1985;139-144.
14. Deschenes R.J., Lorenz L.J., Haun R.S., Roos B.A., Collier K.J., Dixon J.E. Cloning and sequence analysis of a cDNA encoding rat preprocholecystokinin. Proc. Natl. Acad. Sci. USA. 81:1984;726-730.
15. Ding X.-Z., Mocchetti I. Dopaminergic regulation of cholecystokinin mRNA content in rat striatum. Mol. Brain Res. 12:1992;77-83.
16. Falkai P., Bogerts B. Cell loss in the hippocampus of schizophrenics. Eur. Arch. Psychiat. Neur. Sci. 236:1986;154-161.
17. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch. Gen. Psychiatr. 49:1992;538-544.
18. Farmery S.M., Owen F., Poulter M., Crow T.J. Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patients. Life Sci. 36:1985;473-477.
19. Ferrier I.N., Roberts G.W., Crow T.J., et al. Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia. Life Sci. 33:1983;475-482.
20. Frey P. Cholecystokinin octapeptide levels in rat brain are changed after subchronic neuroleptic treatment. Eur. J. Pharmacol. 95:1983;87-92.
21. Fuxe K., Andersson K., Locatelli V., Agnati L.F., Skirboll L., Mutt V. Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas of rat brain following intraventricular injections. Eur. J. Pharmacol. 67:1980;329-331.
22. Garver D.L., Beinfeld M.C., Yao J.K. Cholecystokinin, dopamine and schizophrenia. Psychopharmacol. Bull. 26:1990;377-380.
23. Goldberg T.E., Torrey E.F., Berman K.F., Weinberger D.R. Relations between neuropsychological performance and brain morphological and physiological measures in monozygotic twins discordant for schizophrenia. Psychiatr. Res. 55:1994;51-61.
24. Hanson G.R., Alphs L., Wolf W., Levine R., Lovenberg W. Haloperidolinduced reduction of nigral substance P-like immunoreactivity: a probe for the interactions between dopamine and substance P neuronal systems. J. Pharmacol. Exp. Ther. 218:1981;568-574.
25. Hökfelt T., Rehfeld J.F., Skirboll L., Ivemark B., Goldstein M., Markey K. Evidence of coexistence of dopamine and CCK in meso-limbic neurons. Nature. 285:1980;476-478.
26. Jakob H., Beckmann H. Prenatal development disturbances in the limbic allocortex in schizophrenics. J. Neural. Transm. 65:1986;303-326.
27. Kerwin R.W., Murray R.M. A developmental perspective on the pathology and neurochemistry of the temporal lobe in schizophrenia. Schizophrenia. Res. 7:1992;1-12.
28. Krause J.E., Chirgwin J.M., Carter M.S., Xu Z.S., Hershey A.D. Three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A. Proc. Natl. Acad. Sci. USA. 79:1987;881-885.
29. Krause J.E., Cremins J.D., Carter M.S., Brown E.R., MacDonald M.R. Solution hybridization-nuclease protection assays for sensitive detection of differentially spliced substance P- and neurokinin A-encoding messenger ribonucleic acids. Meth. Enzymol. 168:1989;634-652.
30. Leysen J.E., Niemegeers C.J.E. Neuroleptics. Lajtha A. Handbook in Neurochemistry. Vol. 9:1985;331-361 Plenum, New York.
31. Lindefors N. Amphetamine and haloperidol modulate preprotachykinin-A mRNA expression in rat nucleus accumbens and caudate-putamen. Mol. Brain Res. 13:1992;151-154.
32. Lindefors N., Brené S., Lindén A., Sedvall G., Persson H. CCK peptides and mRNA in the human brain. Progr. Neurobiol. 40:1993;671-690.
33. Lindefors N., Brodin E., Ungerstedt U. Subchronic haloperidol treatment decreases in vivo release of tachykinins in rat substantia nigra. Eur. J. Pharmacol. 161:1989;95-98.
34. Lindefors N., Hurd Y.L., O'Connor W.T., Brené S., Persson H., Ungerstedt U. Amphetamine regulation of acetylcholine and γ-aminobutyric acid in nucleus accumbens. Neuroscience. 48:1992;439-448.
35. Lipska B.K., Weinberger D.R. Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Brain Res. 75:1993;213-222.
36. Maggi C.A. The mammalian tachykinin receptors. Gen. Pharmacol. 26:1995;911-944.
37. Marcus M.M., Nomikos G.G., Malmerfelt A., Zachrisson O., Lindefors N., Svensson T.H. Effect of chronic antipsychotic treatment on preprosomatostatin and preprotachykinin A mRNA levels in the medial prefrontal cortex, the nucleus accumbens and the caudate putamen of the rat. Mol. Brain Res. 45:1997;275-282.
38. Marcus M.M., Nomikos G.G., Svensson T.H. Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens. Eur. Neuropsychopharmacol. 6:1996;29-38.
39. i values. J. Pharmacol. Exp. Ther. 251:1989;238-246.
40. Nawa H., Kotani H., Nakanishi S. Tissue specific generation of two preprotachykin mRNAs from one gene by alternative splicing. Nature. 312:1984;729-734.
41. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, San Diego.
42. Piolti R., Appollonio I., Perego M., et al. Proglumide, a cholecystokinin receptor antagonist, reduces neuroleptic action in Huntington's chorea. Eur. Neurol. 35:1995;344-348.
43. Roberts G.W., Ferrier I.N., Lee Y., et al. Peptides, the limbic lobe and schizophrenia. Brain Res. 288:1983;199-211.
44. Schiffman S.N., Vanderhaeghen J.-J. Distribution of cells containing mRNA encoding cholecystokinin in the rat central nervous system. J. Comp. Neurol. 304:1991;219-233.
45. Schiffman S.N., Vanderhaeghen J.-J. Lesion of the nigrostriatal pathway induces cholecystokinin messenger RNA expression in the rat striatum An in situ hybridization study. Neuroscience. 53:1992;651-663.
46. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1:1987;133-152.
47. Sesack S.R., Bunney B.S. Pharmacological characterization of the receptor mediating electrophysiological responses to dopamine in the rat medial prefrontal cortex: a microiontophoretic study. J. Pharmacol. Exp. Ther. 248:1989;1323-1333.
48. Totterdell S., Smith A.D. Cholecystokinin-immunoreactive boutons in synaptic contact with hippocampal pyramidal neurons that project to the nucleus accumbens. Neuroscience. 19:1986;181-192.
49. van Ree J.M., Gaffori O., de Wied D. In rats, the behavioural profile of CCK-8 related peptides resembles that of antipsychotic agents. Eur. J. Pharmacol. 93:1983;63-78.
50. Verbanck P.M.P., Lotstra F., Giles C., Linkowski P., Mendlewicz J., Vanderhaeghen J.-J. Reduced cholecystokinin immunoreactivity in the cerebrospinal fluid of patients with psychiatric disorders. Life Sci. 34:1984;67-72.
51. Virgo L., Humphries C., Mortimer A., Barnes T., Hirsch S., deBelleroche J. Cholecystokinin mRNA deficit in frontal and temporal cerebral cortex in schizophrenia. Biol. Psychiatr. 37:1995;694-701.
52. Witter M.P., Groenewegen H.J., Lopes da Silva F.H., Lohman A.H.M. Functional organization of the extrinsic and intrinsic circuitry of the parahippocampal region. Prog. Neurobiol. 33:1989;161-253.
53. Young W.S. III, Bonner T.I., Brann M.R. Mescencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc. Natl. Acad. Sci. USA. 83:1986;9827-9831.
54. Young W.S., Mezey F., Siegel R.E. Quantitative In Situ hybridization histochemistry reveals increased levels of corticotropin-releasing factor mRNA after adrenalectomy in rats. Neurosci. Lett. 70:1986;198-203.
55. Zachrisson O., de Belleroche J., Wendt K.R., Hirsch S., Lindefors N. Cholecystokinin CCKB receptor mRNA isoforms: expression in schizophrenic brains. NeuroReport. 10:1999;3265-3268.
56. Zachrisson O., Mathé A.A., Lindefors N. Effects of chronic Lithium and repeated electroconvulsive shock administration on cholecystokinin mRNA expression in the rat brain. Mol. Brain Res. 43:1996;347-350.
57. Zetler G. Neuroleptic-like effects of ceruletide and cholecystokinin octapeptide; interactions with apomorphine methylphenidate and picrotoxin. Eur. J. Pharmacol. 94:1983;261-270.